Every 8-K that CURANEX PHARMACEUTICALS INC (CURX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CURX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CURX filings page.
Curanex Pharmaceuticals Inc (CURX) reports that it has regained compliance with Nasdaq’s minimum bid price requirement. The company had received a notice on November 5, 2025 that its stock traded below the required $1.00 closing bid price for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).
On August 20, 2026, Curanex implemented a 1-for-20 reverse stock split of its outstanding common shares to address this issue. Nasdaq staff subsequently confirmed that from August 20, 2026 through September 2, 2026, the closing bid price was at or above $1.00 for 10 consecutive business days, so the company is now back in full compliance and the matter is considered closed.
Curanex Pharmaceuticals Inc approved and implemented a 1-for-20 reverse stock split of its common stock. A Certificate of Amendment was filed in Nevada to make the reverse split effective at 12:01 a.m. Pacific Time on August 20, 2026.
After effectiveness, every 20 shares of common stock outstanding will automatically convert into one share, resulting in approximately 1,568,241 shares outstanding, based on 31,364,812 shares before the split. Authorized common stock of 475,000,000 shares, authorized preferred stock of 25,000,000 shares, and the $0.0001 par value per share remain unchanged. Fractional shares will be rounded up to the nearest whole share. The purpose of the reverse split is to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement, and the stock will continue to trade under the symbol CURX with a new CUSIP number.
Curanex Pharmaceuticals Inc. provided a first quarter 2026 business update focused on Phyto-N, its lead drug candidate for ulcerative colitis. The company completed a GMP-compliant pilot-scale manufacturing batch and a 28-day dose-range finding toxicology study in rats and dogs, with no treatment-related adverse findings of toxicological significance reported at any dose level, including the maximum feasible dose. These results are intended to support GLP toxicology and other IND-enabling studies for a planned Investigational New Drug submission to the FDA in the fourth quarter of 2026. Curanex also broadened its pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for it, citing a global market estimated at about $2.54 billion in 2024 and projected to reach $3.90 billion by 2033. As of March 31, 2026, the company held approximately $4.0 million in cash and cash equivalents to fund upcoming development activities.
Curanex Pharmaceuticals Inc. received an extension from Nasdaq to regain compliance with the $1.00 minimum bid price required for its common stock to remain listed on the Nasdaq Capital Market. The company now has until November 2, 2026 to lift its closing bid price to at least $1.00 for 10 consecutive business days. Curanex is monitoring its share price and may implement a reverse stock split to meet this requirement, but there is no assurance it will succeed, and failure to comply could result in delisting, subject to a potential appeal to a Nasdaq Hearings Panel.
Curanex Pharmaceuticals Inc. is expanding its drug development pipeline to add cancer cachexia as a new core indication alongside six existing targets such as ulcerative colitis and nonalcoholic fatty liver disease. Cancer cachexia is a severe cancer‑related wasting syndrome with no approved U.S. therapies.
The company cites significant unmet medical need and growing recognition of cancer cachexia, which may affect up to 80% of patients with advanced cancer depending on type and treatment response. Curanex references research estimating the global cancer cachexia market at about $2.54 billion in 2024, projected to reach $3.90 billion by 2033.
Curanex’s lead candidate, Phyto‑N, remains in FDA‑required preclinical studies ahead of a planned IND submission for ulcerative colitis, while management evaluates broader opportunities in serious diseases involving inflammation, metabolic dysfunction and physical decline.
Curanex Pharmaceuticals Inc entered into new executive employment agreements for its two top leaders. On March 2, 2026, the company signed a CEO agreement with Jun Liu, effective March 1, 2026, with a base salary of $393,600 per year and an automobile lease benefit of $3,998 per month. The agreement runs for four years and can be renewed for one-year periods by mutual consent, and includes equity incentive eligibility and standard employee benefits.
Curanex also signed a COO agreement with Dr. Liqin Xie, effective March 1, 2026, with a base salary of $180,000 per year, equity plan eligibility, and standard benefits. His employment is at will and can be ended by either side at any time. Both executives receive three months of salary, continued benefits, and immediate vesting of unvested options or restricted shares if terminated without cause, or for the CEO, if he resigns for defined good reason. The agreements include non-compete, non-solicitation, and confidentiality covenants.
Curanex Pharmaceuticals (CURX) reported a Nasdaq notice that its common stock failed the $1.00 minimum bid price requirement for 30 consecutive business days. Trading on the Nasdaq Capital Market continues under “CURX”.
The company has a 180‑day compliance period until May 4, 2026 to regain compliance by having a closing bid of at least $1.00 for a minimum of ten consecutive business days (subject to Nasdaq staff discretion). If unmet, Curanex may receive an additional 180 days if it satisfies other initial listing standards and notifies Nasdaq of an intent to cure, which may include a reverse stock split. Failing that, the stock would be subject to delisting.
Curanex Pharmaceuticals Inc reported two key actions. The company issued 28,312 unregistered shares of common stock to investor Xiaohong Song under a prior subscription agreement, in exchange for $200,000 that had been subscribed contingent on its initial public offering. This share grant represents 0.1% of 28,312,500 total common shares outstanding at the time of issuance and was made under a private offering exemption.
Curanex also fully repaid two insider loans from Dian Ying Jing, the CEO’s spouse, totaling $400,000 of principal. It paid $408,537.32 in aggregate, including $8,537.32 of accrued interest at a 4.34% annual rate, and did so ahead of the 2027 maturity dates. This prepayment eliminated all of the company’s outstanding debt and removed approximately $26,182.68 of future interest charges that would have accrued through maturity.